Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Add-On lens aims to sharpen vision after complex eye surgeries

NCT ID NCT07452042

Disease control Sponsor: Medical University of Vienna Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Sep 04, 2026 · Updated 2 times

Summary

This study tests a toric add-on lens placed in the eye to correct high astigmatism in people who have already had a corneal transplant and cataract surgery. The goal is to reduce blurry vision from astigmatism without removing the original lens. About 40 participants will be followed for up to 7 months to see if the lens stays stable and improves eyesight.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
toric add-on intraocular lens (implantable lens)
What this could lead to
If successful, this could offer a safe and effective way to correct high astigmatism in people who have had corneal transplant and cataract surgery, potentially improving their vision without additional major surgery.
What could go wrong
This is a small, early-stage study with only 40 participants, so results may not apply to everyone. The lens might rotate or not reduce astigmatism enough, and there are standard surgical risks like infection or inflammation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2026

Expected to finish

Feb 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients scheduled for add-on toric intraocular lens (IOL) implantation due to high postoperative refractive cylinder after keratoplasty and cataract surgery at the University Department of Ophthalmology and Optometry are screened during the preoperative examination. Interested patients are informed about the study's objectives and procedures and, upon consent, are enrolled.

Ages

45 to 95 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Gender: female, male, or diverse * Ophthalmological diagnosis: pseudophakic patients after keratoplasty * Age: 45 to 95 years * Complication-free cataract surgery using phacoemulsification and implantation of a posterior chamber lens. * Complication-free keratoplasty and regular postoperative corneal astigmatism \> 1 diopter (D) * Pupil diameter in mydriasis \> 5.5 mm Exclusion Criteria: * Uncontrolled glaucoma * Proliferative diabetic retinopathy * Iris neovascularization * History of uveitis or iritis * Microphthalmus * Recurrent intraocular inflammation of unknown cause * Blindness in the other eye * Uncontrolled systemic or ocular disease * Pregnancy * Breastfeeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cataract and iol surgery are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cataract

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cataract and iol surgery Keratoplasty Toric intraocular lens stability

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Medical University of Vienna, Department of Ophthalmology and Optometry

    RECRUITING

    Vienna, State of Vienna, 1090, Austria

More trials for these conditions

Other studies related to the condition(s) this trial covers.